Hastings Cent Rep. 2013 Sep;43(5):41-47. doi: 10.1002/hast.199.
Abstract
A special report of The Hastings Center and the Association of American Medical Colleges addressed the
ethical
oversight of learning health systems, which seek to combine
high-quality patient care with routine data collection aimed at
improving patient outcomes. The report contained two position papers,
authored by a number of distinguished bioethicists, and several
commentaries. The position papers urged two changes. First, they urged a
rethinking of our approach to the regulation of human subjects
research, so as to make it easier in the future for learning health
systems to function well. Second, they argued that the rethinking
required dispensing with a strict distinction between research and
therapy, which has been a major tenet of bioethics since the Belmont
Report, which explicated basic
ethical
principles governing human subjects research. We fully support the
objectives of the authors, and we agree that the learning health system
is an important advance that serves patients well. Unnecessary
regulatory burden ought not impede this progress. We disagree, however,
that the best way to bring about these needed changes in the regulatory
environment is to reject the basic distinction between research and
treatment. Unfortunately, we find the arguments in favor of that
strategy to be, in places, reminiscent of what we take to be basic
conceptual errors that hampered the
ethical
understanding of human subjects research prior to adoption of the
Belmont Report. To see why one need not reject the research-treatment
distinction in order to promote learning health systems, we first
investigate in some detail the arguments offered for eliminating the
distinction. We next turn to an issue not addressed by those authors,
namely, the relationship between the physician or investigator and the
patient or subject, to illustrate why the distinction is important and
what is lost if it is jettisoned.
No comments:
Post a Comment